| Quantity: | |
|---|---|
Varenicline Tartrate Tablet is an oral prescription medication indicated for smoking cessation in adults. As a selective partial agonist of the α4β2 nicotinic acetylcholine receptor, it helps reduce nicotine cravings and withdrawal symptoms while diminishing the rewarding effects of smoking. It is widely used as a first-line pharmacological therapy for tobacco dependence.
Varenicline acts as a selective partial agonist at the α4β2 nicotinic acetylcholine receptor (nAChR) in the brain. Its dual mechanism includes:
Stimulating the receptor to relieve nicotine withdrawal symptoms.
Blocking nicotine from fully activating the receptor, reducing the pleasurable effects of smoking.
This unique mechanism helps improve long-term smoking cessation success rates.
Varenicline Tartrate Tablet is indicated for:
Smoking cessation in adults
Reduction of nicotine withdrawal symptoms
Support for tobacco dependence treatment as part of a comprehensive smoking cessation program
First-line therapy for smoking cessation
Reduces nicotine cravings and withdrawal symptoms
Decreases satisfaction derived from smoking
Oral administration with established clinical efficacy
Supported by international clinical guidelines
Treatment typically begins one week before the target quit date with gradual dose titration to improve tolerability. The recommended treatment duration is generally 12 weeks, with an additional course considered for maintaining long-term abstinence.
Varenicline has demonstrated superior smoking cessation rates compared with placebo and several alternative pharmacotherapies in multiple clinical studies. It is recommended by numerous international guidelines for adults motivated to quit smoking.
| Item | Information |
|---|---|
| API | Varenicline Tartrate |
| Dosage Form | Film-coated Tablet |
| Common Strengths | 0.5 mg, 1 mg |
| Route | Oral |
| Therapeutic Class | Smoking Cessation Agent |
Varenicline has been approved in multiple countries for smoking cessation. Generic versions are available in many markets following patent expiry, creating opportunities for global registration, licensing, and commercial partnerships.
Loncom Pharma provides integrated pharmaceutical solutions for global partners, including:
Finished Dosage Form (FDF) supply
API manufacturing
Technology transfer
CDMO services
CTD/eCTD dossier support
International regulatory assistance
It is prescribed to help adults stop smoking by reducing nicotine cravings and withdrawal symptoms.
It partially activates α4β2 nicotinic receptors while preventing nicotine from producing its full rewarding effect.
The standard treatment course is 12 weeks, with extension if additional support is needed to maintain smoking abstinence.
The most common tablet strengths are 0.5 mg and 1 mg.
Varenicline tartrate tablets are typically prescribed as part of a comprehensive smoking cessation program that may include counseling, support groups, or behavioral therapy. The goal of this medication is to help individuals quit smoking by making the experience of smoking less pleasurable and reducing the cravings associated with nicotine withdrawal.
The only nicotine free smoking cessation medication
At present, it is the only smoking cessation drug in the world that does not contain nicotine, and it is also the first smoking cessation prescription drug that does not contain nicotine on the market in China.
Dual regulatory effect
It has dual regulatory effects of agonists and antagonists. During treatment, its excitatory properties can alleviate smoking addiction and withdrawal syndrome, and its antagonism can reduce the satisfaction of smokers in smoking, thereby avoid them from smoking again.
First-line treatment Definite effect
Varenicline tartrate can increase the long-term smoking cessation rate by more than twice
